Netarsudil mesylate - Aerie Pharmaceuticals

Drug Profile

Netarsudil mesylate - Aerie Pharmaceuticals

Alternative Names: AR-13224; AR13324; Netarsudil ophthalmic solution - Aerie Pharmaceuticals; Rhopressa

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals; Cornea Research Foundation of America
  • Class Antiglaucomas; Isoquinolines; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Ocular hypertension; Open-angle glaucoma
  • No development reported Neurological disorders

Most Recent Events

  • 08 May 2018 Aerie Pharmaceuticals plans a regulatory submission in Japan
  • 30 Apr 2018 Launched for Ocular hypertension in USA (Ophthalmic)
  • 30 Apr 2018 Launched for Open angle glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top